Our latest news & events

AACR Annual Meeting 2024, San Diego, CA, April 5-10, BOOTH #1648
Conference
genOway presentation
Event
-
Apr 2024
Read on
8th Annual Tumour Models, San Francisco, CA, Jan 30-Feb 01, 2024
Conference
genOway presentation
Event
-
Jan 2024
Read on
Another technological achievement for genOway's humanized ICP (immune checkpoint) models, used successfully by Curadev Pharma in the preclinical trials of its drug candidate CRD3874 for the treatment of advanced/metastatic solid cancers
2023
IND (Investigational New Drug)
News
-
Aug 2023
Read on
Sigma-Aldrich and genOway expand their CRISPR/Cas9 strategic alliance
2022
Intellectual property
News
-
Sep 2022
Read on
genOway grants the leading UK academic research funder a non-exclusive license for CRISPR/Cas9 technology
2022
Intellectual property
News
-
Jan 2022
Read on
ERS Genomics and genOway enter CRISPR/Cas9 agreement
2021
Intellectual property
News
-
Jun 2021
Read on
After the United States, the European Patent Office delivers the first European patent for the SMASh technology — and genOway has acquired an exclusive license
2021
Intellectual property
News
-
Jan 2021
Read on
genOway obtains €2,3M from the European Union and the Auvergne-Rhône-Alpes Region to develop humanized immune checkpoint models
2021
Grant
News
-
Jan 2021
Read on
genOway and Cyagen have joined forces to form a long-term strategic partnership in the Asia-Pacific region
2020
Partnership
News
-
Dec 2020
Read on
genOway and Merck strengthen CRISPR/Cas9 strategic alliance by extending their partnership to all animal cell models
2020
Partnership
News
-
Jan 2020
Read on
genOway announces the consolidation of a precompetitive consortium to develop and validate humanized immune checkpoint mouse models
2019
Partnership
News
-
Jun 2019
Read on
genOway licenses the Flex technology rights to HHMI for the distribution of its AAV FLEX
2019
Intellectual property
News
-
May 2019
Read on